Regenerative medicine is an emerging field of research that focuses on the repair, replacement or regeneration of cells, tissues or organs to restore impaired function. The field has the potential to address a sizeable market and have a significant impact on the healthcare industry by reducing the burden of certain diseases or conditions where tissue damage is involved. R&D company Fluicell aims to enter this market by focusing on the development of advanced therapy medicinal products (ATMP) based on transplantable microtissues using the company's lead product, Biopixlar. BioStock spoke with Fluicell's CEO Victoire Viannay to learn more about the initiative and its potential impact.
Read the full interview with Victoire Viannay at biostock.se:
https://www.biostock.se/en/fluicell-dives-into-regenerative-medicine-field/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se